Publications

Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Infectious Diseases (Non HPV-Associated)

TitleDisease TargetProduct
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals
Molecular Therapy — March 2015
HIVPENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo
PLoS ONE — December 2013
HIVPENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine
Vaccine — September 2011
HIVPENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
The Journal of Infectious Diseases — March 2019
EbolaINO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
The Journal of Infectious Diseases — October 2018
EbolaINO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
Microbes and Infection — December 2018
ZikaINO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization
The Journal of Infectious Diseases — July 2018
ZikaINO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes
Nature Communications — June 2017
ZikaINO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
npj Vaccines — November 2016
ZikaINO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
Science Translational Medicine — August 2015
MERSINO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine
Vaccine — May 2018
Influenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model
Nature Communications — September 2017
Pseudamonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
The Journal of Infectious Diseases — March 2016
Chikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
Scientific Reports — July 2015
Dengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses
Journal of Hepatology — February 2020
Hepatitis CGLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
The Lancet Infectious Diseases — July 2019
MERSINO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report
The New England Journal of Medicine — October 2017
ZikaINO-4600
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020
COVID-19INO-4800